Is early chemotherapy combined with ADT is beneficial to prostate cancer patients?

This review looked at the results for six previous studies that collectively involved 2,675 prostate cancer patients. The authors concluded that starting ADT patients early with estramustine-based chemotherapy did not improve overall survival. However, docetaxel, when used early with ADT, did improve both overall survival and biochemical progress-free survival. 


Ramos-Esquivel A, Fernandez C, Zeledon Z. 2016. Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. Urol Oncol [Epub ahead of print] 1 April 2016.